Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
about
[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilitySublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomyRadium 223 dichloride for prostate cancer treatmentTargeted Radionuclide Therapy: An Evolution Toward Precision Cancer TreatmentUsefulness of radium-223 in patients with bone metastasesRadium-223 and concomitant therapies: prospects and prudence.Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study.Radium-223 IN metastatic hormone-sensitive high-grade prostate cancer: initial experience.Current approaches to incorporation of radium-223 in clinical practice.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.Radium-223 international early access program: results from the Spanish subset.Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.Targeted α Therapies for the Treatment of Bone Metastases.Current perspectives on bone metastases in castrate-resistant prostate cancer.[177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion.Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.[Radium-223 dichloride in patients with castration-refractory prostate cancer].Single high dose versus repeated bone-targeted radionuclide therapy.Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial.Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
P2860
Q33438196-EF4AE110-3ACD-4E09-8196-B548BFCA56FDQ33656820-5419E983-1815-4EB2-88E7-4734E574BB9FQ37686296-22C51EC5-6E41-463C-9BA3-D4E4042CCBD9Q38937691-9B58F38B-349F-46F9-914E-64CD4C073497Q38995718-E7E32737-547E-41A8-B0A6-B34F4E9CC2ECQ39347702-695CA6CE-094C-4D39-879D-2C43775A68C4Q41192078-8A47A8C4-137F-4A7C-B9C0-F17DDCF450B0Q41279824-8E73C344-AC53-4750-847D-7AE143054ECCQ41354888-155E6702-03A1-447E-A45C-55A2FE7CC08FQ41475179-9991088E-528C-4E03-B589-6FCA04FD28DBQ41656563-034D1937-BDB8-45BF-92F2-76B5287FEB07Q42343422-48EDFDDD-3B1D-48BD-AA7E-0E280F978E69Q46747249-E1719C6B-0C13-48D6-9535-D7B4A749EF89Q47127978-75F526B6-5715-4CE0-BBD4-1D3623C3BA2FQ47146368-CFD9D3DF-5839-43B5-A528-3DFA6C368148Q47212646-FA0B2191-5B78-44BD-A415-BE45E701299FQ47221234-78323169-7684-4D3D-BE9A-19647049421CQ47557622-FE6FA811-BB49-4EA5-9071-A4E35D823B36Q47563547-2FEAEC2D-6CFB-4A82-9ECE-2443D3C9BAB8Q47786425-1E5AD604-F6A3-4762-8994-DA272EB3A30DQ47864550-5ACD52EF-EFD7-44CD-8A2D-D01F7B01937EQ48370675-3C7BF44A-982E-432C-9F7D-0BA0E91454F2Q49271846-C47314C9-DD0C-4ADC-8816-A065FF898C17Q49285273-4593B09B-31BF-4EBF-A19A-B9C96FD7371FQ49546570-E413E4DB-35B9-42E1-ACAB-19D18FFEA132Q49573645-E8D8AB45-4732-4601-80CC-52E461DB7607Q49629938-F195AB2C-BA27-4088-B25B-0794581D6DA0Q49874595-FBED3510-E6DF-45DF-A92E-CA10E09896E8Q50096181-0FE66AF7-A42E-4EA1-9462-A5ABDBACD78FQ50238399-D7CA186B-10AE-4518-BCEC-8A228035F68AQ52565489-C6652B3D-8E8E-4A68-8877-3E92791562C6Q52778839-CBA5FB9D-53E7-456A-802A-F384539A0334Q53830746-3768758F-74F2-4595-84CF-58FDCB877F5FQ55020070-E68CCF3D-CDBE-487E-9329-7CDE6373260FQ55603215-74DF9788-6E8C-469A-9EAF-D4DFF8CD1550Q58759090-1768C4CD-4DD3-4CF9-8E71-94C04750B7EA
P2860
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Radium-223 and concomitant the ...... el, single-arm phase 3b trial.
@ast
Radium-223 and concomitant the ...... el, single-arm phase 3b trial.
@en
type
label
Radium-223 and concomitant the ...... el, single-arm phase 3b trial.
@ast
Radium-223 and concomitant the ...... el, single-arm phase 3b trial.
@en
prefLabel
Radium-223 and concomitant the ...... el, single-arm phase 3b trial.
@ast
Radium-223 and concomitant the ...... el, single-arm phase 3b trial.
@en
P2093
P1433
P1476
Radium-223 and concomitant the ...... el, single-arm phase 3b trial.
@en
P2093
Axel Heidenreich
Daniel Heinrich
Jeremy Gratt
Joe M O'Sullivan
Judith Federhofer
Jérémy Lévy
Kurt Miller
Manfred Wirth
Marcello Tucci
P304
P356
10.1016/S1470-2045(16)30173-5
P577
2016-07-26T00:00:00Z